Comparative Pharmacology
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: COUMADIN versus HEPARIN SODIUM 10 000 UNITS IN DEXTROSE 5 IN PLASTIC CONTAINER.
COUMADIN vs HEPARIN SODIUM 10,000 UNITS IN DEXTROSE 5% IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibits vitamin K epoxide reductase complex 1 (VKORC1), thereby decreasing the synthesis of vitamin K-dependent clotting factors II, VII, IX, and X, as well as anticoagulant proteins C and S.
Heparin binds to antithrombin III, accelerating the inactivation of thrombin (factor IIa) and factor Xa, thereby inhibiting coagulation.
Initial dose 2-5 mg orally once daily, adjusted based on INR response; typical maintenance dose 2-10 mg/day.
For therapeutic anticoagulation, administer intravenous bolus of 80 units/kg followed by continuous infusion at 18 units/kg/hour, adjusted to maintain aPTT 1.5-2.5 times control. For prophylaxis, 5,000 units subcutaneously every 8-12 hours.
None Documented
None Documented
Terminal elimination half-life: 20–60 hours (mean ~40 hours); clinically, anticoagulant effect persists for 2–5 days after stopping due to hepatic synthesis of functional clotting factors.
Mean terminal half-life 1.5 hours (range 1-2 hours) at therapeutic doses; dose-dependent (nonlinear) due to saturable clearance; prolonged in renal impairment (up to 3-6 hours) and hepatic disease.
Renal (approximately 92% as inactive metabolites), fecal/biliary (minor, approximately 8%). Less than 2% excreted unchanged.
Primarily hepatic and reticuloendothelial system metabolism; renal excretion of metabolites accounts for <50% of clearance; minimal biliary/fecal elimination.
Category C
Category A/B
Anticoagulant
Anticoagulant